IRTC iRhythm Technologies Inc

iRhythm Technologies will participate in the 44th Annual J.P. Morgan Healthcare Conference, with management scheduled to present on January 12, 2026. The presentation will be accessible via live and archived webcast on the company's investor website. iRhythm is a digital healthcare company specializing in solutions for detecting, predicting, and preventing disease.

iRhythm Technologies, Inc. (NASDAQ:IRTC) announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on January 12, 2026, and a live webcast of the presentation will be available on the company's investor website. iRhythm specializes in digital healthcare solutions for detecting, predicting, and preventing disease through wearable biosensors and cloud-based analytics.

iRhythm Technologies, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. The company's management is scheduled to present on January 12, 2026, at 8:15 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company’s investor relations website.

Harbor Capital Advisors Inc. significantly reduced its stake in iRhythm Technologies (NASDAQ:IRTC) by 68.3% in the third quarter, now holding 8,995 shares valued at approximately $1.55 million. Despite unprofitability, iRhythm exceeded Q3 earnings and revenue estimates, and analysts maintain a "Moderate Buy" rating with a consensus price target of $206.43. Recent insider selling, including by the CEO, amounted to over $4.7 million in the last three months.

Inspire Investing LLC has acquired a new stake in iRhythm Technologies (NASDAQ:IRTC), purchasing 6,055 shares valued at approximately $1.04 million in Q3. iRhythm Technologies reported strong Q3 earnings, beating analyst estimates with EPS of ($0.06) and revenue of $192.9 million, a 30.8% increase year-over-year. Despite recent insider selling, analysts maintain a "Moderate Buy" rating with an average target price of $206.43 for the company.

iRhythm Technologies has gained significant analyst support and presented new clinical data from Asia-Pacific conferences showcasing its Zio long-term ECG monitoring system's consistent performance across diverse patient populations. This validation, particularly a raised price target from Morgan Stanley, reinforces the company's position in ambulatory cardiac monitoring and highlights its potential for international expansion despite ongoing profitability challenges. Investors are encouraged to consider multiple perspectives on the company's valuation and growth risks.